Clinical trial readout dates for SELLAS Life Sciences Group Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2026.
Next readoutDecember 2026in ~1 month
Upcoming readouts1none in Phase 3
Market cap$2.1B
Cash & investments$135M~13 quarters at last loss rate
SELLAS Life Sciences Group Inc. reported $135M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $10M; at that rate the cash would last about 13 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.